Association between empirical ANTI-MRSA therapy administration and clinical outcomes in patients with severe community-acquired pneumonia

Abstract

Community-acquired pneumonia (CAP) is the leading cause of lower respiratory infections and infectious death worldwide. Antibiotic resistance worsens mortality, prolongs ICU stay and increases the risk of renal failure, although comprehensive data on these outcomes remain scarce. This study evaluates the clinical impact of empirical use of anti-MRSA therapy, such as vancomycin, in patients with severe CAP (sCAP), analysing its relationship with mortality, hospital stay and acute kidney injury.